Ask AI
ProCE Banner Activity

OPERA Cohort: PrEP Coverage and HIV Incidence With LA CAB vs Daily Oral FTC/TDF or FTC/TAF

Conference Coverage
Slideset

In real-world analysis of LA CAB and daily oral PrEP use in the United States, LA CAB coverage was very high and higher than daily oral PrEP coverage. HIV acquisition was rare with both PrEP options but numerically lower with LA CAB despite more frequent HIV testing.

Released: February 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions